person · Reporting owner

Upadhyay Suketu

Disclosed activity across 4 companies

Tapewire entity: 14716
SEC CIK: 0001533149

Reported relationships

Latest disclosed role at each company.

Company	Last reported as	Report date	Published
Endo International plcENDP · Entity 124463	EVP, Chief Financial Officer	September 24, 2016	September 27, 2016
INCYTE CORPINCY · Entity 3182	EVP & Chief Financial Officer	May 04, 2026	May 06, 2026
VERTEX PHARMACEUTICALS INC / MAVRTX · Entity 2875	Director	May 01, 2026	May 05, 2026
ZIMMER BIOMET HOLDINGS, INC.ZBH · Entity 3278	Exec VP, CFO	March 06, 2026	March 10, 2026

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

Endo International plc

Report date September 24, 2016 · Filed September 27, 2016

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Ordinary SharesSEC Table I · non-derivative	Direct	22,412	Reported balance After 2016-09-24 transaction · row 1 1 source row Row 1 · 2016-09-24 · Tax withholding · Disposed 1,618 · Balance 22,412 F1: Thirty-three percent (33%) of Mr. Upadhyay's September 24, 2013 grant of restricted stock units (RSUs) vested on September 24, 2016. F2: These shares represent stock withheld by Endo International plc to satisfy Mr. Upadhyay's tax withholding obligations on shares acquired upon vesting of RSUs. F3: $22.44 represents the vesting price, which is the average of the high and low share price on September 23, 2016, the last business day prior to the vesting day, which was a Saturday.

Filing footnotes · ownership attribution and instrument terms

F1: Thirty-three percent (33%) of Mr. Upadhyay's September 24, 2013 grant of restricted stock units (RSUs) vested on September 24, 2016.

F2: These shares represent stock withheld by Endo International plc to satisfy Mr. Upadhyay's tax withholding obligations on shares acquired upon vesting of RSUs.

F3: $22.44 represents the vesting price, which is the average of the high and low share price on September 23, 2016, the last business day prior to the vesting day, which was a Saturday.

INCYTE CORP

Report date May 04, 2026 · Filed May 06, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	26,343	Reported balance After 2026-05-04 transaction · row 1 Account or security details depend on footnotes; rows are not merged. 1 source row Row 1 · 2026-05-04 · Grant · Acquired 26,343 · Balance 26,343 F1: Represents award of restricted stock units ("RSUs") that will vest 25% annually over four years. The RSUs may be settled only for shares of common stock on a one-for-one basis. F2: Includes the May 4, 2026 aggregate grant of 26,343 shares of common stock.
Employee Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $97.14 · Expires 2036-05-04	Direct	38,429	Reported balance After 2026-05-04 transaction · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · 2026-05-04 · Grant · Acquired 38,429 · Balance 38,429 F3: The May 4, 2026 options become exercisable in 37 installments, with the first 25% vesting after one year and the remainder vesting monthly over three years.
Performance SharesSEC Table II · derivative / convertible security · Expires 2029-05-04	Direct	26,342	Reported balance After 2026-05-04 transaction · row 3 Instrument identity requires review; Table II rows are not merged. 1 source row Row 3 · 2026-05-04 · Grant · Acquired 13,171 · Balance 26,342 F4: Each performance share represents the right to receive up to 200% of one share of common stock. Such shares may be earned based upon the issuer's relative total shareholder return ('TSR') over a three-year performance period beginning on January 1, 2026 as compared to the TSR of companies in a fixed peer group, as set forth in the Performance Share Award Agreement. The earned shares will vest on the third anniversary of the grant date subject to the Reporting Person's continued service with the issuer.

Filing footnotes · ownership attribution and instrument terms

F1: Represents award of restricted stock units ("RSUs") that will vest 25% annually over four years. The RSUs may be settled only for shares of common stock on a one-for-one basis.

F2: Includes the May 4, 2026 aggregate grant of 26,343 shares of common stock.

F3: The May 4, 2026 options become exercisable in 37 installments, with the first 25% vesting after one year and the remainder vesting monthly over three years.

F4: Each performance share represents the right to receive up to 200% of one share of common stock. Such shares may be earned based upon the issuer's relative total shareholder return ('TSR') over a three-year performance period beginning on January 1, 2026 as compared to the TSR of companies in a fixed peer group, as set forth in the Performance Share Award Agreement. The earned shares will vest on the third anniversary of the grant date subject to the Reporting Person's continued service with the issuer.

VERTEX PHARMACEUTICALS INC / MA

Report date May 01, 2026 · Filed May 05, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	1,558	Reported balance After 2026-05-01 transaction · row 1 1 source row Row 1 · 2026-05-01 · Disposition to issuer · Disposed 796 · Balance 1,558 F1: Upon the vesting of restricted stock units granted to Mr. Upadhyay on May 1, 2025, Mr. Upadhyay deferred the receipt of 796 shares of common stock and received instead 796 deferred stock units pursuant to our deferred compensation plan. As a result, Mr. Upadhyay is reporting the disposition of 796 shares of common stock in exchange for an equal number of deferred stock units.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $424.45 · Expires 2036-04-30	Direct	2,866	Reported balance After 2026-05-01 transaction · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · 2026-05-01 · Grant · Acquired 2,866 · Balance 2,866 F2: Fully vested.
Deferred Stock UnitsSEC Table II · derivative / convertible security	Direct	3,595.156	Reported balance After 2026-05-01 transaction · row 3 Instrument identity requires review; Table II rows are not merged. 1 source row Row 3 · 2026-05-01 · Grant · Acquired 796 · Balance 3,595.156 F3: Each deferred stock unit represents one share of common stock and is paid out in common stock upon the earliest to occur of (i) termination of Mr. Upadhyay's service on our board of directors, (ii) a change of control of our company and (iii) Mr. Upadhyay's disability or death. F1: Upon the vesting of restricted stock units granted to Mr. Upadhyay on May 1, 2025, Mr. Upadhyay deferred the receipt of 796 shares of common stock and received instead 796 deferred stock units pursuant to our deferred compensation plan. As a result, Mr. Upadhyay is reporting the disposition of 796 shares of common stock in exchange for an equal number of deferred stock units.

Filing footnotes · ownership attribution and instrument terms

F1: Upon the vesting of restricted stock units granted to Mr. Upadhyay on May 1, 2025, Mr. Upadhyay deferred the receipt of 796 shares of common stock and received instead 796 deferred stock units pursuant to our deferred compensation plan. As a result, Mr. Upadhyay is reporting the disposition of 796 shares of common stock in exchange for an equal number of deferred stock units.

F2: Fully vested.

F3: Each deferred stock unit represents one share of common stock and is paid out in common stock upon the earliest to occur of (i) termination of Mr. Upadhyay's service on our board of directors, (ii) a change of control of our company and (iii) Mr. Upadhyay's disability or death.

ZIMMER BIOMET HOLDINGS, INC.

Report date March 06, 2026 · Filed March 10, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	69,485	Ending reported balance After 2026-03-06 transaction · row 4 4 source rows · reconciled sequence Row 1 · 2026-03-06 · Exercise / conversion · Acquired 10,217 · Balance 71,502 Row 2 · 2026-03-06 · Tax withholding · Disposed 4,547 · Balance 66,955 F1: Represents shares withheld by Zimmer Biomet Holdings, Inc. (the "Company") to satisfy tax withholding obligations on the vesting of restricted stock units ("RSUs"). Row 3 · 2026-03-06 · Exercise / conversion · Acquired 4,559 · Balance 71,514 Row 4 · 2026-03-06 · Tax withholding · Disposed 2,029 · Balance 69,485 F1: Represents shares withheld by Zimmer Biomet Holdings, Inc. (the "Company") to satisfy tax withholding obligations on the vesting of restricted stock units ("RSUs").
Restricted Stock UnitsSEC Table II · derivative / convertible security · Expires 2026-03-06	Direct	0	Reported balance After 2026-03-06 transaction · row 5 Instrument identity requires review; Table II rows are not merged. 1 source row Row 5 · 2026-03-06 · Exercise / conversion · Disposed 10,217 · Balance 0 F2: Each RSU represents a contingent right to receive one share of Company common stock.
Restricted Stock UnitsSEC Table II · derivative / convertible security · Expires 2026-03-06	Direct	0	Reported balance After 2026-03-06 transaction · row 6 Instrument identity requires review; Table II rows are not merged. 1 source row Row 6 · 2026-03-06 · Exercise / conversion · Disposed 4,559 · Balance 0 F2: Each RSU represents a contingent right to receive one share of Company common stock.

Filing footnotes · ownership attribution and instrument terms

F1: Represents shares withheld by Zimmer Biomet Holdings, Inc. (the "Company") to satisfy tax withholding obligations on the vesting of restricted stock units ("RSUs").

F2: Each RSU represents a contingent right to receive one share of Company common stock.

Transaction history

JSON API

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction date	Company	Activity / security	Shares / units	Reported price	Reported value	Details
May 04, 2026 Filed May 6, 2026 20:34 UTC	INCYTE CORP INCY · Entity 3182	GrantPerformance Shares · Derivative	13,171	$0.00	$0.00	Disclosure SEC source: 0001533149-26-000014 · wk-form4_1778099692.xml · derivative · entry 3 Upadhyay Suketu · CIK 0001533149 · EVP & Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 26,342 Underlying: Common Stock · 13,171 shares Expires 2029-05-04 F4 · derivative.exercise_price: Each performance share represents the right to receive up to 200% of one share of common stock. Such shares may be earned based upon the issuer's relative total shareholder return ('TSR') over a three-year performance period beginning on January 1, 2026 as compared to the TSR of companies in a fixed peer group, as set forth in the Performance Share Award Agreement. The earned shares will vest on the third anniversary of the grant date subject to the Reporting Person's continued service with the issuer. F4 · derivative.exercise_date: Each performance share represents the right to receive up to 200% of one share of common stock. Such shares may be earned based upon the issuer's relative total shareholder return ('TSR') over a three-year performance period beginning on January 1, 2026 as compared to the TSR of companies in a fixed peer group, as set forth in the Performance Share Award Agreement. The earned shares will vest on the third anniversary of the grant date subject to the Reporting Person's continued service with the issuer. Read SEC document
May 04, 2026 Filed May 6, 2026 20:34 UTC	INCYTE CORP INCY · Entity 3182	GrantEmployee Stock Option (right to buy) · Derivative	38,429	$0.00 Strike: $97.14	$0.00	Disclosure SEC source: 0001533149-26-000014 · wk-form4_1778099692.xml · derivative · entry 2 Upadhyay Suketu · CIK 0001533149 · EVP & Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 38,429 Underlying: Common Stock · 38,429 shares Expires 2036-05-04 F3 · derivative.exercise_date: The May 4, 2026 options become exercisable in 37 installments, with the first 25% vesting after one year and the remainder vesting monthly over three years. F3 · balance_after: The May 4, 2026 options become exercisable in 37 installments, with the first 25% vesting after one year and the remainder vesting monthly over three years. Read SEC document
May 04, 2026 Filed May 6, 2026 20:34 UTC	INCYTE CORP INCY · Entity 3182	GrantCommon Stock	26,343	$0.00	$0.00	Disclosure SEC source: 0001533149-26-000014 · wk-form4_1778099692.xml · nonDerivative · entry 1 Upadhyay Suketu · CIK 0001533149 · EVP & Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 26,343 F1 · shares: Represents award of restricted stock units ("RSUs") that will vest 25% annually over four years. The RSUs may be settled only for shares of common stock on a one-for-one basis. F2 · balance_after: Includes the May 4, 2026 aggregate grant of 26,343 shares of common stock. Read SEC document
May 01, 2026 Filed May 5, 2026 21:44 UTC	VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875	GrantDeferred Stock Units · Derivative	796	Not disclosed	Not disclosed	Disclosure SEC source: 0000875320-26-000193 · wk-form4_1778017445.xml · derivative · entry 3 Upadhyay Suketu · CIK 0001533149 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,595.156 Underlying: Common Stock · 796 shares Expires not disclosed F3 · derivative.exercise_price: Each deferred stock unit represents one share of common stock and is paid out in common stock upon the earliest to occur of (i) termination of Mr. Upadhyay's service on our board of directors, (ii) a change of control of our company and (iii) Mr. Upadhyay's disability or death. F1 · price: Upon the vesting of restricted stock units granted to Mr. Upadhyay on May 1, 2025, Mr. Upadhyay deferred the receipt of 796 shares of common stock and received instead 796 deferred stock units pursuant to our deferred compensation plan. As a result, Mr. Upadhyay is reporting the disposition of 796 shares of common stock in exchange for an equal number of deferred stock units. F3 · derivative.exercise_date: Each deferred stock unit represents one share of common stock and is paid out in common stock upon the earliest to occur of (i) termination of Mr. Upadhyay's service on our board of directors, (ii) a change of control of our company and (iii) Mr. Upadhyay's disability or death. F3 · derivative.expiration_date: Each deferred stock unit represents one share of common stock and is paid out in common stock upon the earliest to occur of (i) termination of Mr. Upadhyay's service on our board of directors, (ii) a change of control of our company and (iii) Mr. Upadhyay's disability or death. Read SEC document
May 01, 2026 Filed May 5, 2026 21:44 UTC	VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875	GrantStock Option (Right to Buy) · Derivative	2,866	$0.00 Strike: $424.45	$0.00	Disclosure SEC source: 0000875320-26-000193 · wk-form4_1778017445.xml · derivative · entry 2 Upadhyay Suketu · CIK 0001533149 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,866 Underlying: Common Stock · 2,866 shares Expires 2036-04-30 F2 · derivative.exercise_date: Fully vested. Read SEC document
May 01, 2026 Filed May 5, 2026 21:44 UTC	VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875	Disposition to issuerCommon Stock	796	Not disclosed	Not disclosed	Disclosure SEC source: 0000875320-26-000193 · wk-form4_1778017445.xml · nonDerivative · entry 1 Upadhyay Suketu · CIK 0001533149 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,558 F1 · price: Upon the vesting of restricted stock units granted to Mr. Upadhyay on May 1, 2025, Mr. Upadhyay deferred the receipt of 796 shares of common stock and received instead 796 deferred stock units pursuant to our deferred compensation plan. As a result, Mr. Upadhyay is reporting the disposition of 796 shares of common stock in exchange for an equal number of deferred stock units. Read SEC document
April 15, 2026 Filed Apr 17, 2026 20:20 UTC	VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875	GrantDeferred Stock Units · Derivative	80.508	$442.50	$35,624.79	Disclosure SEC source: 0000875320-26-000163 · wk-form4_1776457233.xml · derivative · entry 1 Upadhyay Suketu · CIK 0001533149 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,799.156 Underlying: Common Stock · 80.508 shares Expires not disclosed F1 · derivative.exercise_price: Each deferred stock unit represents one share of common stock and is paid out in common stock upon the earliest to occur of (i) termination of Mr. Upadhyay's service on our board of directors, (ii) a change of control of our company and (iii) Mr. Upadhyay's disability or death. F1 · derivative.exercise_date: Each deferred stock unit represents one share of common stock and is paid out in common stock upon the earliest to occur of (i) termination of Mr. Upadhyay's service on our board of directors, (ii) a change of control of our company and (iii) Mr. Upadhyay's disability or death. F1 · derivative.expiration_date: Each deferred stock unit represents one share of common stock and is paid out in common stock upon the earliest to occur of (i) termination of Mr. Upadhyay's service on our board of directors, (ii) a change of control of our company and (iii) Mr. Upadhyay's disability or death. Read SEC document
March 06, 2026 Filed Mar 10, 2026 20:13 UTC	ZIMMER BIOMET HOLDINGS, INC. ZBH · Entity 3278	Exercise / conversionRestricted Stock Units · Derivative	4,559	$0.00	$0.00	Disclosure SEC source: 0001533149-26-000009 · form4-03102026_080309.xml · derivative · entry 6 Upadhyay Suketu · CIK 0001533149 · Exec VP, CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 4,559 shares Expires 2026-03-06 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of Company common stock. Read SEC document
March 06, 2026 Filed Mar 10, 2026 20:13 UTC	ZIMMER BIOMET HOLDINGS, INC. ZBH · Entity 3278	Exercise / conversionRestricted Stock Units · Derivative	10,217	$0.00	$0.00	Disclosure SEC source: 0001533149-26-000009 · form4-03102026_080309.xml · derivative · entry 5 Upadhyay Suketu · CIK 0001533149 · Exec VP, CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 10,217 shares Expires 2026-03-06 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of Company common stock. Read SEC document
March 06, 2026 Filed Mar 10, 2026 20:13 UTC	ZIMMER BIOMET HOLDINGS, INC. ZBH · Entity 3278	Tax withholdingCommon Stock	2,029	$92.54	$187,763.66	Disclosure SEC source: 0001533149-26-000009 · form4-03102026_080309.xml · nonDerivative · entry 4 Upadhyay Suketu · CIK 0001533149 · Exec VP, CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 69,485 F1 · shares: Represents shares withheld by Zimmer Biomet Holdings, Inc. (the "Company") to satisfy tax withholding obligations on the vesting of restricted stock units ("RSUs"). Read SEC document
March 06, 2026 Filed Mar 10, 2026 20:13 UTC	ZIMMER BIOMET HOLDINGS, INC. ZBH · Entity 3278	Exercise / conversionCommon Stock	4,559	$0.00	$0.00	Disclosure SEC source: 0001533149-26-000009 · form4-03102026_080309.xml · nonDerivative · entry 3 Upadhyay Suketu · CIK 0001533149 · Exec VP, CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 71,514 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
March 06, 2026 Filed Mar 10, 2026 20:13 UTC	ZIMMER BIOMET HOLDINGS, INC. ZBH · Entity 3278	Tax withholdingCommon Stock	4,547	$92.54	$420,779.38	Disclosure SEC source: 0001533149-26-000009 · form4-03102026_080309.xml · nonDerivative · entry 2 Upadhyay Suketu · CIK 0001533149 · Exec VP, CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 66,955 F1 · shares: Represents shares withheld by Zimmer Biomet Holdings, Inc. (the "Company") to satisfy tax withholding obligations on the vesting of restricted stock units ("RSUs"). Read SEC document
March 06, 2026 Filed Mar 10, 2026 20:13 UTC	ZIMMER BIOMET HOLDINGS, INC. ZBH · Entity 3278	Exercise / conversionCommon Stock	10,217	$0.00	$0.00	Disclosure SEC source: 0001533149-26-000009 · form4-03102026_080309.xml · nonDerivative · entry 1 Upadhyay Suketu · CIK 0001533149 · Exec VP, CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 71,502 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
February 25, 2026 Filed Feb 27, 2026 21:04 UTC	ZIMMER BIOMET HOLDINGS, INC. ZBH · Entity 3278	Exercise / conversionRestricted Stock Units · Derivative	6,364	$0.00 Strike: $0.00	$0.00	Disclosure SEC source: 0001533149-26-000007 · form4-02272026_090211.xml · derivative · entry 3 Upadhyay Suketu · CIK 0001533149 · Exec VP, CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 12,726 Underlying: Common Stock · 6,364 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: One-third of the RSUs vested on February 25, 2026. The remaining RSUs vest one-half on each of February 25, 2027 and February 25, 2028. F2 · derivative.expiration_date: One-third of the RSUs vested on February 25, 2026. The remaining RSUs vest one-half on each of February 25, 2027 and February 25, 2028. Read SEC document
February 25, 2026 Filed Feb 27, 2026 21:04 UTC	ZIMMER BIOMET HOLDINGS, INC. ZBH · Entity 3278	Tax withholdingCommon Stock	2,832	$99.51	$281,812.32	Disclosure SEC source: 0001533149-26-000007 · form4-02272026_090211.xml · nonDerivative · entry 2 Upadhyay Suketu · CIK 0001533149 · Exec VP, CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 61,285 F1 · shares: Represents shares withheld by Zimmer Biomet Holdings, Inc. (the "Company") to satisfy tax withholding obligations on the vesting of restricted stock units ("RSUs"). Read SEC document
February 25, 2026 Filed Feb 27, 2026 21:04 UTC	ZIMMER BIOMET HOLDINGS, INC. ZBH · Entity 3278	Exercise / conversionCommon Stock	6,364	$0.00	$0.00	Disclosure SEC source: 0001533149-26-000007 · form4-02272026_090211.xml · nonDerivative · entry 1 Upadhyay Suketu · CIK 0001533149 · Exec VP, CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 64,117 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
February 20, 2026 Filed Feb 25, 2026 01:58 UTC	ZIMMER BIOMET HOLDINGS, INC. ZBH · Entity 3278	GrantRestricted Stock Units · Derivative	21,701	$0.00	$0.00	Disclosure SEC source: 0001533149-26-000005 · form4-02252026_010204.xml · derivative · entry 4 Upadhyay Suketu · CIK 0001533149 · Exec VP, CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 21,701 Underlying: Common Stock · 21,701 shares Expires not disclosed F2 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of Company common stock. F3 · derivative.exercise_date: Vests annually over three years in increments of one-third each year, commencing February 20, 2027. F3 · derivative.expiration_date: Vests annually over three years in increments of one-third each year, commencing February 20, 2027. Read SEC document
February 20, 2026 Filed Feb 25, 2026 01:58 UTC	ZIMMER BIOMET HOLDINGS, INC. ZBH · Entity 3278	Exercise / conversionRestricted Stock Units · Derivative	5,445	$0.00	$0.00	Disclosure SEC source: 0001533149-26-000005 · form4-02252026_010204.xml · derivative · entry 3 Upadhyay Suketu · CIK 0001533149 · Exec VP, CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,445 Underlying: Common Stock · 5,445 shares Expires 2026-02-20 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of Company common stock. Read SEC document
February 20, 2026 Filed Feb 25, 2026 01:58 UTC	ZIMMER BIOMET HOLDINGS, INC. ZBH · Entity 3278	Tax withholdingCommon Stock	2,446	$98.62	$241,224.52	Disclosure SEC source: 0001533149-26-000005 · form4-02252026_010204.xml · nonDerivative · entry 2 Upadhyay Suketu · CIK 0001533149 · Exec VP, CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 57,753 F1 · shares: Represents shares withheld by Zimmer Biomet Holdings, Inc. (the "Company") to satisfy tax withholding obligations on the vesting of restricted stock units ("RSUs"). Read SEC document
February 20, 2026 Filed Feb 25, 2026 01:58 UTC	ZIMMER BIOMET HOLDINGS, INC. ZBH · Entity 3278	Exercise / conversionCommon Stock	5,445	$0.00	$0.00	Disclosure SEC source: 0001533149-26-000005 · form4-02252026_010204.xml · nonDerivative · entry 1 Upadhyay Suketu · CIK 0001533149 · Exec VP, CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 60,199 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
February 19, 2026 Filed Feb 23, 2026 22:34 UTC	ZIMMER BIOMET HOLDINGS, INC. ZBH · Entity 3278	GrantRestricted Stock Units · Derivative	10,217	$0.00	$0.00	Disclosure SEC source: 0001533149-26-000003 · form4-02232026_100241.xml · derivative · entry 1 Upadhyay Suketu · CIK 0001533149 · Exec VP, CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,217 Underlying: Common Stock · 10,217 shares Expires 2026-03-06 F1 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of Company common stock. F2 · shares: On March 6, 2023, the reporting person was granted performance-based RSUs, with the number of RSUs earned to be determined based on the extent to which certain performance conditions were met for a performance period of 2023 - 2025. As determined on February 19, 2026, based on actual performance, the reporting person earned 10,217 RSUs, which will vest on March 6, 2026. F2 · derivative.underlying_shares: On March 6, 2023, the reporting person was granted performance-based RSUs, with the number of RSUs earned to be determined based on the extent to which certain performance conditions were met for a performance period of 2023 - 2025. As determined on February 19, 2026, based on actual performance, the reporting person earned 10,217 RSUs, which will vest on March 6, 2026. Read SEC document
January 15, 2026 Filed Jan 20, 2026 21:48 UTC	VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875	GrantDeferred Stock Units · Derivative	80.316	$443.56	$35,624.96	Disclosure SEC source: 0000875320-26-000008 · wk-form4_1768945675.xml · derivative · entry 1 Upadhyay Suketu · CIK 0001533149 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,718.648 Underlying: Common Stock · 80.316 shares Expires not disclosed F1 · derivative.exercise_price: Each deferred stock unit represents one share of common stock and is paid out in common stock upon the earliest to occur of (i) termination of Mr. Upadhyay's service on our board of directors, (ii) a change of control of our company and (iii) Mr. Upadhyay's disability or death. F1 · derivative.exercise_date: Each deferred stock unit represents one share of common stock and is paid out in common stock upon the earliest to occur of (i) termination of Mr. Upadhyay's service on our board of directors, (ii) a change of control of our company and (iii) Mr. Upadhyay's disability or death. F1 · derivative.expiration_date: Each deferred stock unit represents one share of common stock and is paid out in common stock upon the earliest to occur of (i) termination of Mr. Upadhyay's service on our board of directors, (ii) a change of control of our company and (iii) Mr. Upadhyay's disability or death. Read SEC document
November 10, 2025 Filed Nov 12, 2025 21:07 UTC	ZIMMER BIOMET HOLDINGS, INC. ZBH · Entity 3278	Exercise / conversionRestricted Stock Units · Derivative	10,632	$0.00	$0.00	Disclosure SEC source: 0001533149-25-000007 · form4-11122025_091137.xml · derivative · entry 3 Upadhyay Suketu · CIK 0001533149 · Exec VP, CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 10,632 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of the Company's common stock. F3 · derivative.exercise_date: Earned performance-based RSUs vested on November 10, 2025. F3 · derivative.expiration_date: Earned performance-based RSUs vested on November 10, 2025. Read SEC document
November 10, 2025 Filed Nov 12, 2025 21:07 UTC	ZIMMER BIOMET HOLDINGS, INC. ZBH · Entity 3278	Tax withholdingCommon Stock	4,731	$87.73	$415,050.63	Disclosure SEC source: 0001533149-25-000007 · form4-11122025_091137.xml · nonDerivative · entry 2 Upadhyay Suketu · CIK 0001533149 · Exec VP, CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 54,754 F1 · shares: Represents shares withheld by Zimmer Biomet Holdings, Inc. (the "Company") to satisfy tax withholding obligations on the vesting of the restricted stock units ("RSUs"). Read SEC document
November 10, 2025 Filed Nov 12, 2025 21:07 UTC	ZIMMER BIOMET HOLDINGS, INC. ZBH · Entity 3278	Exercise / conversionCommon Stock	10,632	$0.00	$0.00	Disclosure SEC source: 0001533149-25-000007 · form4-11122025_091137.xml · nonDerivative · entry 1 Upadhyay Suketu · CIK 0001533149 · Exec VP, CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 59,485 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
October 24, 2025 Filed Nov 3, 2025 22:42 UTC	ZIMMER BIOMET HOLDINGS, INC. ZBH · Entity 3278	GrantRestricted Stock Units · Derivative	10,632	$0.00	$0.00	Disclosure SEC source: 0001533149-25-000005 · form4-11032025_101125.xml · derivative · entry 1 Upadhyay Suketu · CIK 0001533149 · Exec VP, CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,632 Underlying: Common Stock · 10,632 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Zimmer Biomet Holdings, Inc. common stock. F2 · shares: On September 1, 2023, the reporting person was granted performance-based RSUs, with the number of RSUs earned to be determined based on the extent to which certain performance conditions were met for a performance period of October 1, 2024 to September 30, 2025. As determined on October 24, 2025, based on actual performance, the reporting person earned 10,632 RSUs with a scheduled vesting date of November 10, 2025. F3 · derivative.exercise_date: Earned RSUs vest on November 10, 2025. F3 · derivative.expiration_date: Earned RSUs vest on November 10, 2025. Read SEC document
October 15, 2025 Filed Oct 17, 2025 20:05 UTC	VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875	GrantDeferred Stock Units · Derivative	86.825	$410.31	$35,625.17	Disclosure SEC source: 0001533149-25-000003 · wk-form4_1760731543.xml · derivative · entry 1 Upadhyay Suketu · CIK 0001533149 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,638.332 Underlying: Common Stock · 86.825 shares Expires not disclosed F1 · derivative.exercise_price: Each deferred stock unit represents one share of common stock and is paid out in common stock upon the earliest to occur of (i) termination of Mr. Upadhyay's service on our board of directors, (ii) a change of control of our company and (iii) Mr. Upadhyay's disability or death. F1 · derivative.exercise_date: Each deferred stock unit represents one share of common stock and is paid out in common stock upon the earliest to occur of (i) termination of Mr. Upadhyay's service on our board of directors, (ii) a change of control of our company and (iii) Mr. Upadhyay's disability or death. F1 · derivative.expiration_date: Each deferred stock unit represents one share of common stock and is paid out in common stock upon the earliest to occur of (i) termination of Mr. Upadhyay's service on our board of directors, (ii) a change of control of our company and (iii) Mr. Upadhyay's disability or death. Read SEC document
July 15, 2025 Filed Jul 17, 2025 20:09 UTC	VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875	GrantDeferred Stock Units · Derivative	75.904	$469.34	$35,624.78	Disclosure SEC source: 0000875320-25-000210 · wk-form4_1752782953.xml · derivative · entry 1 Upadhyay Suketu · CIK 0001533149 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,551.507 Underlying: Common Stock · 75.904 shares Expires not disclosed F1 · derivative.exercise_price: Each deferred stock unit represents one share of common stock and is paid out in common stock upon the earliest to occur of (i) termination of Mr. Upadhyay's service on our board of directors, (ii) a change of control of our company and (iii) Mr. Upadhyay's disability or death. F1 · derivative.exercise_date: Each deferred stock unit represents one share of common stock and is paid out in common stock upon the earliest to occur of (i) termination of Mr. Upadhyay's service on our board of directors, (ii) a change of control of our company and (iii) Mr. Upadhyay's disability or death. F1 · derivative.expiration_date: Each deferred stock unit represents one share of common stock and is paid out in common stock upon the earliest to occur of (i) termination of Mr. Upadhyay's service on our board of directors, (ii) a change of control of our company and (iii) Mr. Upadhyay's disability or death. Read SEC document
May 01, 2025 Filed May 5, 2025 21:00 UTC	VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875	GrantDeferred Stock Units · Derivative	1,001	Not disclosed	Not disclosed	Disclosure SEC source: 0000875320-25-000190 · wk-form4_1746478850.xml · derivative · entry 3 Upadhyay Suketu · CIK 0001533149 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,475.603 Underlying: Common Stock · 1,001 shares Expires not disclosed F3 · derivative.exercise_price: Each deferred stock unit represents one share of common stock and is paid out in common stock upon the earliest to occur of (i) termination of Mr. Upadhyay's service on our board of directors, (ii) a change of control of our company and (iii) Mr. Upadhyay's disability or death. F2 · price: Upon the vesting of restricted stock units granted to Mr. Upadhyay on May 1, 2024, Mr. Upadhyay deferred the receipt of 1,001 shares of common stock and received instead 1,001 deferred stock units pursuant to our deferred compensation plan. As a result, Mr. Upadhyay is reporting the disposition of 1,001 shares of common stock in exchange for an equal number of deferred stock units. F3 · derivative.exercise_date: Each deferred stock unit represents one share of common stock and is paid out in common stock upon the earliest to occur of (i) termination of Mr. Upadhyay's service on our board of directors, (ii) a change of control of our company and (iii) Mr. Upadhyay's disability or death. F3 · derivative.expiration_date: Each deferred stock unit represents one share of common stock and is paid out in common stock upon the earliest to occur of (i) termination of Mr. Upadhyay's service on our board of directors, (ii) a change of control of our company and (iii) Mr. Upadhyay's disability or death. Read SEC document
May 01, 2025 Filed May 5, 2025 21:00 UTC	VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875	Disposition to issuerCommon Stock	1,001	Not disclosed	Not disclosed	Disclosure SEC source: 0000875320-25-000190 · wk-form4_1746478850.xml · nonDerivative · entry 2 Upadhyay Suketu · CIK 0001533149 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,354 F2 · price: Upon the vesting of restricted stock units granted to Mr. Upadhyay on May 1, 2024, Mr. Upadhyay deferred the receipt of 1,001 shares of common stock and received instead 1,001 deferred stock units pursuant to our deferred compensation plan. As a result, Mr. Upadhyay is reporting the disposition of 1,001 shares of common stock in exchange for an equal number of deferred stock units. Read SEC document
May 01, 2025 Filed May 5, 2025 21:00 UTC	VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875	GrantCommon Stock	796	$0.00	$0.00	Disclosure SEC source: 0000875320-25-000190 · wk-form4_1746478850.xml · nonDerivative · entry 1 Upadhyay Suketu · CIK 0001533149 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,355 F1 · shares: Restricted stock unit award that vests, subject to certain limited exceptions, on the first anniversary of the grant date. Read SEC document
April 15, 2025 Filed Apr 17, 2025 20:08 UTC	VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875	GrantDeferred Stock Units · Derivative	71.607	$497.51	$35,625.20	Disclosure SEC source: 0000875320-25-000166 · wk-form4_1744920530.xml · derivative · entry 1 Upadhyay Suketu · CIK 0001533149 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,474.603 Underlying: Common Stock · 71.607 shares Expires not disclosed F1 · derivative.exercise_price: Each deferred stock unit represents one share of common stock and is paid out in common stock upon the earliest to occur of (i) termination of Mr. Upadhyay's service on our board of directors, (ii) a change of control of our company and (iii) Mr. Upadhyay's disability or death. F1 · derivative.exercise_date: Each deferred stock unit represents one share of common stock and is paid out in common stock upon the earliest to occur of (i) termination of Mr. Upadhyay's service on our board of directors, (ii) a change of control of our company and (iii) Mr. Upadhyay's disability or death. F1 · derivative.expiration_date: Each deferred stock unit represents one share of common stock and is paid out in common stock upon the earliest to occur of (i) termination of Mr. Upadhyay's service on our board of directors, (ii) a change of control of our company and (iii) Mr. Upadhyay's disability or death. Read SEC document
March 06, 2025 Filed Mar 7, 2025 22:34 UTC	ZIMMER BIOMET HOLDINGS, INC. ZBH · Entity 3278	Exercise / conversionRestricted Stock Units · Derivative	4,560	$0.00	$0.00	Disclosure SEC source: 0001062993-25-004969 · form4.xml · derivative · entry 3 Upadhyay Suketu · CIK 0001533149 · Exec. VP, CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,559 Underlying: Common Stock · 4,560 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of Zimmer Biomet Holdings, Inc. common stock. F3 · derivative.exercise_date: 4,560 of the RSUs vested on March 6, 2025. The remaining RSUs vest on March 6, 2026 F3 · derivative.expiration_date: 4,560 of the RSUs vested on March 6, 2025. The remaining RSUs vest on March 6, 2026 Read SEC document
March 06, 2025 Filed Mar 7, 2025 22:34 UTC	ZIMMER BIOMET HOLDINGS, INC. ZBH · Entity 3278	Tax withholdingCommon Stock	2,029	$104.86	$212,760.94	Disclosure SEC source: 0001062993-25-004969 · form4.xml · nonDerivative · entry 2 Upadhyay Suketu · CIK 0001533149 · Exec. VP, CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 48,853 F1 · shares: Represents shares withheld by the Company to satisfy tax withholding obligations on the vesting of restricted stock units ("RSUs"). Read SEC document
March 06, 2025 Filed Mar 7, 2025 22:34 UTC	ZIMMER BIOMET HOLDINGS, INC. ZBH · Entity 3278	Exercise / conversionCommon Stock	4,560	$0.00	$0.00	Disclosure SEC source: 0001062993-25-004969 · form4.xml · nonDerivative · entry 1 Upadhyay Suketu · CIK 0001533149 · Exec. VP, CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 50,882 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
February 25, 2025 Filed Feb 28, 2025 02:31 UTC	ZIMMER BIOMET HOLDINGS, INC. ZBH · Entity 3278	GrantRestricted Stock Units · Derivative	19,090	$0.00	$0.00	Disclosure SEC source: 0001062993-25-003850 · form4.xml · derivative · entry 1 Upadhyay Suketu · CIK 0001533149 · Exec. VP, CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 19,090 Underlying: Common Stock · 19,090 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Zimmer Biomet Holdings, Inc. common stock. F2 · derivative.exercise_date: Vests annually over three years in increments of one-third each year, commencing February 25, 2026. F2 · derivative.expiration_date: Vests annually over three years in increments of one-third each year, commencing February 25, 2026. Read SEC document
February 20, 2025 Filed Feb 24, 2025 21:08 UTC	ZIMMER BIOMET HOLDINGS, INC. ZBH · Entity 3278	Exercise / conversionRestricted Stock Units · Derivative	5,446	$0.00	$0.00	Disclosure SEC source: 0001062993-25-003336 · form4.xml · derivative · entry 3 Upadhyay Suketu · CIK 0001533149 · Exec. VP, CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,890 Underlying: Common Stock · 5,446 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of Company common stock. F3 · derivative.exercise_date: One-third of the RSUs vested on February 20, 2025. The remaining RSUs vest one-half on each of February 20, 2026 and February 20, 2027. F3 · derivative.expiration_date: One-third of the RSUs vested on February 20, 2025. The remaining RSUs vest one-half on each of February 20, 2026 and February 20, 2027. Read SEC document
February 20, 2025 Filed Feb 24, 2025 21:08 UTC	ZIMMER BIOMET HOLDINGS, INC. ZBH · Entity 3278	Tax withholdingCommon Stock	2,423	$103.46	$250,683.58	Disclosure SEC source: 0001062993-25-003336 · form4.xml · nonDerivative · entry 2 Upadhyay Suketu · CIK 0001533149 · Exec. VP, CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 46,322 F1 · shares: Represents shares withheld by Zimmer Biomet Holdings, Inc. (the "Company") to satisfy tax withholding obligations on the vesting of restricted stock units ("RSUs"). Read SEC document
February 20, 2025 Filed Feb 24, 2025 21:08 UTC	ZIMMER BIOMET HOLDINGS, INC. ZBH · Entity 3278	Exercise / conversionCommon Stock	5,446	$0.00	$0.00	Disclosure SEC source: 0001062993-25-003336 · form4.xml · nonDerivative · entry 1 Upadhyay Suketu · CIK 0001533149 · Exec. VP, CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 48,745 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
February 18, 2025 Filed Feb 19, 2025 22:59 UTC	ZIMMER BIOMET HOLDINGS, INC. ZBH · Entity 3278	Exercise / conversionRestricted Stock Units · Derivative	21,622	$0.00	$0.00	Disclosure SEC source: 0001062993-25-002913 · form4.xml · derivative · entry 4 Upadhyay Suketu · CIK 0001533149 · Exec. VP, CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 21,622 shares Expires 2025-02-18 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of Company common stock. Read SEC document
February 18, 2025 Filed Feb 19, 2025 22:59 UTC	ZIMMER BIOMET HOLDINGS, INC. ZBH · Entity 3278	Tax withholdingCommon Stock	8,155	$101.00	$823,655.00	Disclosure SEC source: 0001062993-25-002913 · form4.xml · nonDerivative · entry 2 Upadhyay Suketu · CIK 0001533149 · Exec. VP, CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 43,299 F2 · shares: Represents shares withheld by Zimmer Biomet Holdings, Inc. (the "Company") to satisfy tax withholding obligations on the vesting of restricted stock units ("RSUs"). Read SEC document
February 18, 2025 Filed Feb 19, 2025 22:59 UTC	ZIMMER BIOMET HOLDINGS, INC. ZBH · Entity 3278	Exercise / conversionCommon Stock	21,622	$0.00	$0.00	Disclosure SEC source: 0001062993-25-002913 · form4.xml · nonDerivative · entry 1 Upadhyay Suketu · CIK 0001533149 · Exec. VP, CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 51,454 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes 87 shares acquired under the Employee Stock Purchase Plan through February 18, 2025. Read SEC document
February 14, 2025 Filed Feb 19, 2025 22:59 UTC	ZIMMER BIOMET HOLDINGS, INC. ZBH · Entity 3278	GrantRestricted Stock Units · Derivative	21,622	$0.00	$0.00	Disclosure SEC source: 0001062993-25-002913 · form4.xml · derivative · entry 3 Upadhyay Suketu · CIK 0001533149 · Exec. VP, CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 21,622 Underlying: Common Stock · 21,622 shares Expires 2025-02-18 F3 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of Company common stock. F4 · shares: On February 18, 2022, the reporting person was granted performance-based RSUs, with the number of RSUs earned to be determined based on the extent to which certain performance conditions were met for a performance period of 2022 - 2024. As determined on February 14, 2025, based on actual performance, the reporting person earned 21,622 RSUs, which vested on February 18, 2025. F4 · derivative.underlying_shares: On February 18, 2022, the reporting person was granted performance-based RSUs, with the number of RSUs earned to be determined based on the extent to which certain performance conditions were met for a performance period of 2022 - 2024. As determined on February 14, 2025, based on actual performance, the reporting person earned 21,622 RSUs, which vested on February 18, 2025. Read SEC document
November 10, 2024 Filed Nov 12, 2024 21:32 UTC	ZIMMER BIOMET HOLDINGS, INC. ZBH · Entity 3278	Exercise / conversionRestricted Stock Units · Derivative	15,948	$0.00	$0.00	Disclosure SEC source: 0001062993-24-018908 · form4.xml · derivative · entry 4 Upadhyay Suketu · CIK 0001533149 · Exec. VP, CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 15,948 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of Zimmer Biomet Holdings, Inc. common stock. F5 · derivative.exercise_date: Earned RSUs vested on November 10, 2024. F5 · derivative.expiration_date: Earned RSUs vested on November 10, 2024. Read SEC document
November 10, 2024 Filed Nov 12, 2024 21:32 UTC	ZIMMER BIOMET HOLDINGS, INC. ZBH · Entity 3278	Tax withholdingCommon Stock	7,097	$108.48	$769,882.56	Disclosure SEC source: 0001062993-24-018908 · form4.xml · nonDerivative · entry 2 Upadhyay Suketu · CIK 0001533149 · Exec. VP, CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 29,745 F2 · shares: Represents shares withheld by the Company to satisfy tax withholding obligations on the vesting of restricted stock units ("RSUs"). Read SEC document
November 10, 2024 Filed Nov 12, 2024 21:32 UTC	ZIMMER BIOMET HOLDINGS, INC. ZBH · Entity 3278	Exercise / conversionCommon Stock	15,948	$0.00	$0.00	Disclosure SEC source: 0001062993-24-018908 · form4.xml · nonDerivative · entry 1 Upadhyay Suketu · CIK 0001533149 · Exec. VP, CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 36,842 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes 130 shares acquired under the Company's Employee Stock Purchase Plan since the date of the filing of the reporting person's last Form 4. Read SEC document
November 08, 2024 Filed Nov 12, 2024 21:32 UTC	ZIMMER BIOMET HOLDINGS, INC. ZBH · Entity 3278	GrantRestricted Stock Units · Derivative	15,948	$0.00	$0.00	Disclosure SEC source: 0001062993-24-018908 · form4.xml · derivative · entry 3 Upadhyay Suketu · CIK 0001533149 · Exec. VP, CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 15,948 Underlying: Common Stock · 15,948 shares Expires not disclosed F3 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of Zimmer Biomet Holdings, Inc. common stock. F4 · shares: On September 1, 2023, the reporting person was granted performance-based RSUs, with the number of RSUs earned to be determined based on the extent to which certain performance conditions were met for a performance period of October 1, 2023 to September 30, 2024. As determined on November 8, 2024, based on actual performance, the reporting person earned 15,948 RSUs with a scheduled vesting date of November 10, 2024. F5 · derivative.exercise_date: Earned RSUs vested on November 10, 2024. F5 · derivative.expiration_date: Earned RSUs vested on November 10, 2024. Read SEC document
May 01, 2024 Filed May 3, 2024 20:26 UTC	VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875	GrantDeferred Stock Units · Derivative	1,168	Not disclosed	Not disclosed	Disclosure SEC source: 0000875320-24-000133 · wk-form4_1714767971.xml · derivative · entry 3 Upadhyay Suketu · CIK 0001533149 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,402.996 Underlying: Common Stock · 1,168 shares Expires not disclosed F3 · derivative.exercise_price: Each deferred stock unit represents one share of common stock and is paid out in common stock upon the earliest to occur of (i) termination of Mr. Upadhyay's service on our board of directors, (ii) a change of control of our company and (iii) Mr. Upadhyay's disability or death. F2 · price: Upon the vesting of restricted stock units granted to Mr. Upadhyay on May 1, 2023, Mr. Upadhyay deferred the receipt of 1,168 shares of common stock and received instead 1,168 deferred stock units pursuant to our deferred compensation plan. As a result, Mr. Upadhyay is reporting the disposition of 1,168 shares of common stock in exchange for an equal number of deferred stock units. F3 · derivative.exercise_date: Each deferred stock unit represents one share of common stock and is paid out in common stock upon the earliest to occur of (i) termination of Mr. Upadhyay's service on our board of directors, (ii) a change of control of our company and (iii) Mr. Upadhyay's disability or death. F3 · derivative.expiration_date: Each deferred stock unit represents one share of common stock and is paid out in common stock upon the earliest to occur of (i) termination of Mr. Upadhyay's service on our board of directors, (ii) a change of control of our company and (iii) Mr. Upadhyay's disability or death. Read SEC document
May 01, 2024 Filed May 3, 2024 20:26 UTC	VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875	Disposition to issuerCommon Stock	1,168	Not disclosed	Not disclosed	Disclosure SEC source: 0000875320-24-000133 · wk-form4_1714767971.xml · nonDerivative · entry 2 Upadhyay Suketu · CIK 0001533149 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,559 F2 · price: Upon the vesting of restricted stock units granted to Mr. Upadhyay on May 1, 2023, Mr. Upadhyay deferred the receipt of 1,168 shares of common stock and received instead 1,168 deferred stock units pursuant to our deferred compensation plan. As a result, Mr. Upadhyay is reporting the disposition of 1,168 shares of common stock in exchange for an equal number of deferred stock units. Read SEC document
May 01, 2024 Filed May 3, 2024 20:26 UTC	VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875	GrantCommon Stock	1,001	$0.00	$0.00	Disclosure SEC source: 0000875320-24-000133 · wk-form4_1714767971.xml · nonDerivative · entry 1 Upadhyay Suketu · CIK 0001533149 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,727 F1 · shares: Restricted stock unit award that vests, subject to certain limited exceptions, on the first anniversary of the grant date. Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.